ReviewMicrobes and infection2015
Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections.
Review in Microbes and infection, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- A Narrative Review on the Recent Insights Into the Pathogenicity and Potential Role of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in the Emergence of "Disease X".Health science reports · 2025Article
- Quantitative assay to analyze neutralization and inhibition of authentic Middle East respiratory syndrome coronavirus.Medical microbiology and immunology · 2024Article
- Discovery of Antivirals Using Phage Display.Viruses · 2021Review
- Middle East Respiratory Syndrome (MERS) Virus-Pathophysiological Axis and the Current Treatment Strategies.AAPS PharmSciTech · 2021Review
- Immunological Approaches to the Treatment of New Coronavirus Infection (Review).Sovremennye tekhnologii v meditsine · 2021Review
- Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.Virologica Sinica · 2020Review
- An update on antiviral antibody-based biopharmaceuticals.International immunopharmacology · 2020Review
- Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.The Lancet. Infectious diseases · 2020Article
- Immunology of COVID-19: Current State of the Science.Immunity · 2020Review
- Identification of Human Single-Domain Antibodies against SARS-CoV-2.Cell host & microbe · 2020Article
- Coronavirus membrane fusion mechanism offers a potential target for antiviral development.Antiviral research · 2020Review
- Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection.Emerging microbes & infections · 2019Article
- Review
- A review of treatment modalities for Middle East Respiratory Syndrome.The Journal of antimicrobial chemotherapy · 2016Review
- From SARS to MERS: evidence and speculation.Frontiers of medicine · 2016Review
- Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus.Emerging infectious diseases · 2016Article
- Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3.Emerging microbes & infections · 2016Article
- Critically ill patients with Middle East respiratory syndrome coronavirus infection.Critical care (London, England) · 2016Review
- Article
- Molecular Basis of Coronavirus Virulence and Vaccine Development.Advances in virus research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The recent Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak poses a serious threat to public health. Here, we summarize recent advances in identifying human neutralizing monoclonal antibodies (mAbs) against MERS-CoV, describe their mechanisms of action, and analyze their potential for treatment of MERS-CoV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.